BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy.

METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy.

RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001).

CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer. Copyright 2003 Massachusetts Medical Society

Written by:
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED.   Are you the author?
M.D. Anderson Cancer Center, Houston, USA.

Reference: N Engl J Med. 2003 Aug 28;349(9):859-66.


PubMed Abstract
PMID: 12944571

 

 

Calendar

Upcoming Events
October 27-November 1, 2024
The Western Section of the AUA's 100th Annual Meeting

Location: Kauai, Hawaii
at the Grand Hyatt Kauai
October 30-November 2, 2024
The South-Central Section of the AUA's 103rd Annual Meeting


Location: Colorado Springs, Colorado
at The Broadmoor
November 14-16, 2024
The annual meeting gathers professionals to learn, exchange ideas and to celebrate LUGPA’s over 15 years of commitment to advancing independent urology. This year’s Annual Meeting is LUGPA’s most important event - with three days of education and networking available for our constituents: urologists, advanced practice providers, administrators, managers, and healthcare industry supporters.

Location: Chicago, IL
at the Chicago Marriott Magnificent Mile Hotel
November 14-16, 2024
Hosted by the Kidney Cancer Association (KCA), the International Kidney Cancer Symposium presents a variety of speakers from various fields and backgrounds, all coming together to discuss advances in the field, results of research, and other news in the industry.

Location: Louisville, Kentucky
Venue to be announced.
December 4-6, 2024
The Society of Urologic Oncology (SUO)'s mission is to enable qualified members primarily interested in the care of patients with malignant GU diseases to meet for the purpose of discussion, development, and implementation of ideas to improve care. The organization strives to stimulate research and teaching in urologic oncology, disseminate the principles of urologic oncology to the medical profession at large, bring urologists into a society whose work is entirely/principally in malignant disease, be the most qualified organization on matters of urologic oncology, and standardize fellowship training in urologic oncology. 

Location: Dallas, Texas
at the Sheraton Dallas Hotel

Program and meeting information to be released soon!
December 13-15, 2024
The Florida Urological Society's 76th Annual Meeting

Location: Orlando, Florida
at the Loew's Royal Pacific